Denver celebrates five years of Healthy Food for Denver's Kids initiative
DENVER (KDVR) — Denver is celebrating the halfway point of its 10-year-long Healthy Food for Denver's Kids initiative.
The initiative has invested more than $85 million into over 100 local organizations that work to increase access to nutritious food and food-based education for youth and their families, the city said Thursday.
Lawsuit against Purina plant's 'rancid' odor dismissed
'Every child and family deserve the chance to access affordable, nutritious food,' Denver Mayor Mike Johnston said in a statement.
The Healthy Food for Denver's Kids initiative was put in place following a voter-approved ballot initiative in 2018, with funding currently in place through 2029.
'Healthy Food for Denver's Kids has transformed how we support families in our city: making healthy meals more available, empowering communities, and ensuring equity regardless of where families live or their budgets,' Johnston said. This milestone is a powerful reminder of what we can achieve when we invest in our kids and their futures.'
Since 2019, the city said Healthy Food for Denver's Kids has:
Reached more than 149,000 families across Denver
Served more than 40 million healthy and 'culturally relevant' meals and snacks
Supported programming delivered in 33 languages
Funded efforts in schools, nonprofits and public agencies focused on nutrition, food justice and youth empowerment
The city is marking the milestone with a public celebration on Saturday at the Denver Zoo at the Zoo Gardens Plaza from 10 a.m. to 2 p.m. Zoo admission is required.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Why Oscar Health, Inc. (OSCR) Soared On Thursday
We recently published a list of . In this article, we are going to take a look at where Oscar Health, Inc. (NYSE:OSCR) stands against other best-performing stocks on Thursday. Oscar Health snapped a five-day losing streak on Thursday, jumping 10.6 percent to close at $15.65 apiece as investors resorted to bargain-hunting while waiting for more concrete developments on the Trump administration's Medicare Advantage review. Earlier this year, lawmakers passed a $5-trillion tax-and-spending package that shaves as much as $900 billion in Medicaid, which servers over 70 million low-income households. A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. Now, Senate Republicans to broaden savings by looking for supposed inefficiencies in the Medicare program for senior citizens. In the first quarter of the year, Oscar Health, Inc. (NYSE:OSCR) registered a 55-percent increase in attributable net income of $275 million versus the $177 million registered in the same period last year. Revenues rose by 42 percent to $3.046 billion from $2.142 billion year-on-year. Overall, OSCR ranks 5th on our list of best-performing stocks on Thursday. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 hours ago
- Yahoo
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
18 hours ago
- Yahoo
Uptick in tick bites reported in Central Pennsylvania emergency rooms
JOHNSTOWN, Pa. (WTAJ) — With summer temperatures reaching Central Pennsylvania, emergency rooms are noticing an uptick in ticks. 'The seasons are now changing and so we're doing a lot more outdoor stuff,' said Nsikak Daniel, M.D., an emergency room physician at Conemaugh Memorial Medical Center in Johnstown. 'Ticks are just one of those things you kind of get when you go out into the woods.' While children and older adults may have the most adverse reactions to tick bites, everyone should take precautions. Juniata College receives approval from state nursing board for new nursing program 'Wear clothing that covers you up, you know, socks and stuff like that with your shoes. Insect repellents sometimes can help,' Daniels said. Lyme Disease is a common illness carried by ticks, often characterized by a bullseye–shaped rash around a bite. While it's become more prevalent, Daniels said it's not the only thing you should worry about. 'One of the complications a lot of people don't think about is something that's called anaplasmosis. It's a very serious, tick borne illness and it's something that can affect your bloodstream. It can affect your organs and cause organ damage,' Daniels said. If you get bit and have any concerns that you did not remove the tick or notice signs of infection such as fever or a rash, you should go to the emergency room immediately. Veterinarians also said they're seeing a rise in bites and infections in dogs. They said the best way to keep your furry friend safe is to use medications and repellents, mow your lawn and avoid high risk areas like tall grass and wooded areas during tick season. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
